Investment seen as further validation of the corporate nutrition benefit market and its ability to manage workforce health and costs.
LISBON, Portugal, Sept. 16, 2025 — Nutrium, an all-in-one corporate nutrition solution that helps millions of patients worldwide create personalized meal plans, track progress, manage chronic diseases, maintain weight, and lead healthier lives overall, announced today it secured $12 million in Series A funding. Vesalius Biocapital led the round; Lince Capital, Indico Capital Partners, and Beta Capital also participated. While the Nutrium platform already reaches millions of patients, connecting them to the world’s largest network of more than 350,000 registered dietitians in over 90 countries, this investment further solidifies the company’s global position in the corporate nutrition market.
A patient uses the Nutrium software to review personal progress.
The timing of the capital infusion is especially notable as soaring healthcare costs driven by obesity and the growing demand for GLP-1 medications make sustainable, expert-led non-pharmaceutical wellness solutions that improve health outcomes essential for employers and executives.
“Nutrition has become a business priority for companies navigating the challenges of obesity and the rapid adoption of GLP-1 treatments,” said André Santos, CEO and co-founder of Nutrium. “With this funding, we’re ready to expand our reach, strengthen our expert network, and deliver even greater outcomes for our clients and their people worldwide.”
As Nutrium’s clinically grounded corporate nutrition benefit, Nutrium Care delivers measurable financial and health outcomes that directly address rising corporate healthcare costs. On average, corporate partners see three times the return on their investment, with a five percent reduction in member weight in the first four months, reduced prescription medication needs, and increased employee productivity. Additionally, the program is a fraction of the cost of GLP-1 medication and has significantly higher retention and adherence rates. Though impressive, Nutrium’s remarkable 400% revenue growth last year is what caught the eye of its latest investor.
“At Vesalius, we are increasingly aware of the challenges associated with obesity and the need for better nutrition care, which is often overlooked as a key solution for such chronic conditions. We believe that Nutrium will be the solution of choice for employers and individuals that would like to improve their overall health.” said Qasim Al-Zawawi, Principal at Vesalius Biocapital. “We are impressed by the growth and achievements accomplished by Nutrium, and are thrilled to be leading the Series A, supporting the Nutrium team in their goal of making the world healthier.”
Stephan de Moraes, Managing General Partner at the independent venture capital fund manager, Indico Capital Partners, also shared his enthusiasm about the funding round and the company’s promise. “Since the start, the team at Nutrium had a clear vision about the key role that nutrition would play in health and wellbeing. We have been fortunate to back that ambition and help the team find a path to fulfill the promise of wellbeing, a key component of longevity, which is a huge and rapidly expanding market.”
Building on its track record with leading global brands such as Wellhub, Adidas, Vodafone, Talkspace, and several others, Nutrium expects to strengthen its U.S. operations and forge more strategic alliances with health plans and consultants to scale nutrition care even faster.
About Nutrium Founded in 2015 in Portugal, Nutrium transforms how companies care for employee health through Nutrium Care, a complete corporate nutrition program combining 1:1 dietitian support, proactive digital coaching, and measurable impact. Backed by the world’s largest network of dietitians, Nutrium has already improved millions of lives and remains committed to making healthy eating practical, personal, and proven worldwide.
The Veterinary Company Enters New Phase of Growth, With Continued Investment in its Tech Infrastructure and Comprehensive Care Model
LOS ANGELES, Sept. 16, 2025 — Modern Animal, the pioneering veterinary company dedicated to reimagining pet care, today announced that it has achieved a nine-figure revenue run rate and has raised $46 million in funding, led by Addition, True Ventures, and Upfront Ventures, with participation from Founders Fund, alongside a strategic expansion of its Board of Directors.
Mark Suster, managing partner at Upfront Ventures, which has backed Modern Animal since its 2019 seed round, joins the company’s board alongside Karen Boone, former CFO of Restoration Hardware and current board member of Peloton, Sonos, CoreWeave, and Rivian; Tony Conrad, partner at True Ventures; and Robbie Horwitz, partner at Addition.
Modern Animal is focused on redefining healthcare for pet parents, whether in clinic or online through 24/7 virtual care, from the first puppy and kitten visits through every life stage. This funding supports that vision, expanding services including an integrated pharmacy and e-commerce platform, extended urgent care hours, and expanded specialty care. Leveraging its proprietary technology infrastructure, the company is continuing to double down on its AI-powered tools and proprietary technology stack to fully automate administrative tasks, improve workflows, and support clinical decision-making, substantially enhancing operational efficiency and helping veterinarians deliver even higher-quality care.
“This is an important moment for Modern Animal,” said Steven Eidelman, the company’s founder & CEO. “We’re growing our care offerings and investing in the technology that puts us in a unique position to better serve pets and their parents, empower our veterinary teams, and build long-term value in a fast-changing industry. We’re focused on deploying our capital strategically – always in ways that improve the quality of care we deliver, and the experience for the providers of that care.”
The new funding comes on the heels of a period of significant growth for Modern Animal, including 85% year‑over‑year revenue growth in 2024 to a now $100 million annual run rate. These results highlight the solid foundation built since the company’s inception, with upcoming advancements expected to play a key role in accelerating its path to sustainable profitability.
“In a world where all investors can think about is AI all the time, it’s refreshing to back a company that, while leveraging technology, is completely dedicated to something we universally love — animals,” said Mark Suster, managing partner at Upfront Ventures. “Steven and his team have built a consumer brand in the veterinary care space that is equally loved by vets as it is by modern, young, tech-savvy animal owners. Modern Animal has already shown its ability to transform the industry and will continue setting the standard for what veterinary care can be.”
Modern Animal has 27 clinics across California, Texas, and Colorado. Having served more than 100,000 pets, the company is strengthening its presence in markets where it has already built significant capacity and is expanding its services to provide an even more reliable, comprehensive solution for pet parents. At the same time, the company remains committed to creating a more fulfilling and sustainable work environment for veterinary professionals.
About Modern Animal Modern Animal is a veterinary company with a mission to bring humanity back to veterinary medicine on behalf of pets, their parents, and the veterinary community. Leveraging its own technology platform, 24/7 virtual care, and state-of-the-art clinics, Modern Animal offers members an all-in-one experience that connects every aspect of their pet’s health, delivering personalized care and exceptional service at every touchpoint. For more information, visit www.modernanimal.com, and follow @modernanimal on Instagram and @modernanimalvet on TikTok.
NEW YORK, Sept. 16, 2025 — ExSight Ventures, a venture capital firm dedicated to investing in transformative ophthalmology innovations, today announced its investment in RevOpsis Therapeutics, a biotechnology company pioneering next-generation therapies for retinal diseases.
RevOpsis is developing a novel class of multispecific antibody-based treatments designed to address significant unmet needs in ophthalmology, with an initial focus on wet age-related macular degeneration (AMD) and diabetic eye disease. The company’s proprietary platform integrates advanced protein engineering with validated biological pathways to deliver therapies that aim to improve durability, efficacy, and patient outcomes.
“We are thrilled to support RevOpsis in its mission to bring breakthrough therapies to patients suffering from vision-threatening conditions,” said Firas Rahhal, MD, General Partner at ExSight Ventures and Retina Vitreous Associates Medical Group in Los Angeles. “Our investment reflects our strong belief in both the scientific foundation of RevOpsis’ platform and the experienced leadership team driving its development.”
The funding will enable RevOpsis to accelerate preclinical development of its lead candidate and expand its pipeline of novel ophthalmic assets.
“ExSight Ventures is a leading investor in the ophthalmology space, and their support is a strong validation of our approach,” said Ram Bhandari, MD, Chief Executive Officer and Co-founder of RevOpsis Therapeutics. “This partnership will help us advance our pipeline toward clinical development and bring us closer to providing patients with more effective and longer-lasting treatment options. ExSight Ventures has a proven track record of backing companies developing innovative solutions in eye care, and this investment further demonstrates its commitment to supporting the next wave of therapeutic breakthroughs in ophthalmology.”
About RevOpsis Therapeutics
Founded in 2018, RevOpsis Therapeutics is a privately held, next-generation biopharmaceutical company spearheading innovation in ophthalmic therapies. Guided by a team of leading physicians, scientists, and business leaders, we are dedicated to leveraging our proprietary Rev-Mod Platform to develop and commercialize groundbreaking treatments for chronic multifactorial diseases. With a steadfast commitment to responsibly advancing patient care, we aim to usher in a new era of improved disease management and extended disease remission.
Leveraging the proprietary Rev-Mod platform, RO-104 is RevOpsis’ current lead candidate. Engineered as a first-in-class fully human modular tri-specific biologic designed to address all three clinically validated dominant angiogenic pathways (VEGF-A, VEGF-C, Ang-2) implicated in retinal vascular disease progression, including neovascular age-related macular degeneration (nAMD). RO-104 represents a significant innovative advancement in the treatment landscape for retinal vascular diseases. For more information, please visit www.revopsis.com.
About ExSight Ventures
ExSight Ventures (EV) is a venture capital firm built to serve an underserved corner of the innovation economy: early-stage life sciences. With deep clinical expertise and venture discipline, we stand as trusted partners for innovators transforming ophthalmology. Our commitment is to back pioneering teams advancing breakthrough innovations to patients who need them most. www.exsightventures.com
Investment supports market expansion and platform development, enabling PayNearMe’s clients to derive strategic advantage from payment experience
SANTA CLARA, Calif., Sept. 16, 2025 — Today, PayNearMe, a leading fintech transforming the payment experience for non-commerce businesses and their customers, announced a $50 million Series E investment from AVP (Atlantic Vantage Point) through its Growth Fund I. The investment will accelerate PayNearMe’s expansion into new markets and fuel ongoing investment in products that simplify the end-to-end payment experience for its clients.
“PayNearMe has redefined what it means to deliver a modern payment experience. The company is uniquely positioned to solve challenges in a space long underserved and overlooked,” said Elizabeth de Saint-Aignan, General Partner and Head of Growth Fund, North America at AVP. “PayNearMe’s vision and proven execution are changing how non-commerce businesses approach payments, and we’re excited to support them in this next stage of growth.”
PayNearMe pioneered Payment Experience Management, a combination of software and money movement services that optimize every touchpoint in the payment journey across customers, support and operations. By accelerating payments and reducing the total cost of acceptance, PayNearMe helps its clients improve cash flow and profitability.
“For too long, payments have been treated only as a cost of doing business,” said Danny Shader, CEO of PayNearMe. “We see improving payments as a powerful opportunity to help businesses differentiate, drive customer satisfaction, and improve business results. AVP’s funding will allow us to deliver the benefits of Payment Experience Management to more clients and in new markets.”
As part of its ongoing product evolution and continued investment in Payment Experience Management, PayNearMe has renamed its platform to PayXM™—the industry’s first platform that is purpose-built to dramatically improve the end-to-end payment experience. PayXM enables businesses to manage the entire payment journey, for all major forms of payment and through the most popular channels, with a single platform and integration.
About AVP
AVP is an independent global investment platform dedicated to high-growth, tech (from deep-tech to tech-enabled) companies across Europe and North America. The firm manages more than €2.5 billion in assets across four strategies: venture, early growth, growth, and fund of funds. Its multi-stage platform combines global research with local execution to drive investment. Since its establishment in 2016, AVP has invested in more than 60 technology companies and in over 60 funds through its Fund of Funds strategy. Beyond providing capital, AVP’s dedicated expansion team works closely with founders, offering expertise, connections and resources needed to unlock growth opportunities, and create lasting value through meaningful collaborations. More information at www.avpcap.com.
About PayNearMe
PayNearMe is redefining the way businesses and their customers experience payments. With PayXM™, the industry’s first platform purpose-built for Payment Experience Management, every touchpoint in the payment journey becomes easy— driving customer satisfaction, accelerating payments, and reducing the total cost of acceptance. The platform supports all major payment types and channels, from PayPal, Venmo, Cash App Pay, Apple Pay, Google Pay, cards and ACH to cash at more than 62,000 U.S. retail locations.
Thousands of businesses across industries, including consumer lending, iGaming and online sports betting, property management, and tolling, rely on PayNearMe to manage the end-to-end payment experience with a single platform and integration.
SAN JOSE, Calif., Sept. 16, 2025 — Figure, the AI robotics company developing autonomous general-purpose humanoid robots, today announced it has exceeded more than $1 billion in committed capital through its Series C financing round, at a post-money valuation of $39 billion. The funding will accelerate the company’s efforts to bring general-purpose humanoid robots into real-world environments at scale.
The round was led by Parkway Venture Capital with significant investment from Brookfield Asset Management, NVIDIA, Macquarie Capital, Intel Capital, Align Ventures, Tamarack Global, LG Technology Ventures, Salesforce, T-Mobile Ventures, and Qualcomm Ventures.
“This milestone is critical to unlocking the next stage of growth for humanoid robots, scaling out our AI platform Helix and BotQ manufacturing,” said Brett Adcock, Founder and CEO of Figure. “Support from new partners, alongside the continued backing of our existing investors, reflects both Figure’s position as the market leader and a shared belief in a future where this technology becomes a natural part of daily life.”
This capital raise milestone supports Figure’s momentum across three core areas—all designed to unlock the full capabilities of Helix, Figure’s AI system for embodied intelligence:
Scaling humanoid robots into homes and commercial operations. Figure is expanding production manufacturing at BotQ and real-world deployments, enabling robots to assist with household and commercial workforce tasks.
Building next-generation NVIDIA GPU infrastructure to accelerate training and simulation. This compute foundation will power Helix’s core models for perception, reasoning, and control.
Launching advanced data collection efforts. These include data collection of human video and multimodal sensory inputs, to improve how robots understand and operate in complex, dynamic settings. These real-world datasets are essential to scaling Helix’s capabilities.
About Figure
Figure is an AI robotics company developing autonomous general-purpose humanoid robots. The goal of the company is to ship humanoid robots with human level intelligence. Its robots are engineered to perform a variety of tasks in the home and commercial markets. Figure is headquartered in San Jose, CA.
Lauren B. Leichtman, Cindy Gallop, Vlada Bortnik & Andrea Holland to Headline
SAN DIEGO, Sept. 16, 2025 — The Stella Foundation’s 12th Annual Women’s Venture Summit (WVS), will return to San Diego, CA from September 23–25, 2025. This year’s theme, Building Boldly, reflects the Summit’s mission: to fuel the growth of women founders, expand the ranks of women investors, and rewrite the future of venture capital.
The Stella Foundation’s 12th Annual Women’s Venture Summit (WVS), will return to San Diego, CA from September 23–25, 2025.
The 2025 keynote lineup brings together trailblazers across finance, tech, culture, and leadership. Lauren B. Leichtman, Co-Founder of Levine Leichtman Capital Partners and Chairwoman of San Diego Wave FC, recently recognized by Forbes as the world’s first woman private equity billionaire, will share her journey scaling capital and impact. Cindy Gallop, fearless entrepreneur and founder of MakeLoveNotPorn, will take the stage with her unapologetic message on equity and inclusion. Vlada Bortnik, CEO & Co-Founder of Marco Polo, will discuss building technology with purpose at scale, and Andrea Holland, award-winning executive coach, will bring insight on leading with bold strategy in high-stakes moments.
Far more than a speaker series, the three-day event features transformative workshops, fireside chats, and interactive sessions designed to close the funding gap. Attendees will dive into sessions on Alternative Capital Pathways for Founders, Personal Finance Best Practices for Investors, Structuring Funds and Syndicates, and Breaking Into VC & Angel Investing, and many more. Networking lounges and curated meetups provide rare access for emerging investors to connect directly with fund managers, and for founders to build relationships with active capital providers.
At the heart of the summit is the Women’s Fast Pitch SemiFinals, where six women founders, selected from regional competitions across the U.S., will compete live for more than $50,000 in grants, investments, and in-kind support. The pitch competition has become a signature feature of WVS, with past participants going on to secure venture funding, national media coverage, and acquisition opportunities.
“In a year where political and economic headwinds are dismantling resources, funding, and programs for women, we’re choosing to do the opposite,” said Flossie Hall, CEO of the Stella Foundation. “Women’s Venture Summit doubles down on women, providing the capital, connections, and knowledge they need to get funded. This summit isn’t just an event, it’s a bold response to the moment we’re in – and a launchpad for the companies and funds that will define our future economy.”
Dr. Silvia Mah, Founder & Chair of the Board of the Stella Foundation, added: “When women invest in women, we create exponential impact. WVS is the catalyst where innovation, capital, and purpose intersect – and where the cycle of empowerment truly accelerates.”
Since its inception, WVS has facilitated more than $250 million in capital for women-led ventures. The 2025 summit is supported by sponsors includingThe Impact Seat Foundation, Comcast Lift Labs, Cooley LLP, Holland & Knight LLP, She Invests, and a growing coalition of partners committed to equity in venture.
The Women’s Venture Summit is a national gathering that builds bridges between female founders and investors. Designed for aspiring investors, seasoned entrepreneurs, and community partners, the Summit combines education, connection, and capital to increase funding for women-led businesses and grow the number of women writing checks.
About the Stella Foundation
Founded in 2012, the Stella Foundation connects women founders and investors to the right resource at the right time. With a community of more than 10,000 women served annually and over $250 million in facilitated funding, Stella offers curriculum, advisory, capital access, and convening events—including Women’s Fast Pitch and Women’s Venture Summit—to drive equality in venture. Learn more at stella.co.
Media Contact Laura Henson HVM Communications [email protected] 917-539-7812
Crave is helping early-stage founders win shelf space, drive demand and raise capital.
CHARLOTTE, N.C., Sept. 16, 2025 — Crave Ventures today announced its official launch as a service-for-equity, brokerage-backed growth partner for emerging consumer packaged goods (CPG) brands.
The launch comes after a successful multi-month pilot period in which the firm onboarded a small group of hand-selected portfolio brands and pressure-tested its model.
The Team At Crave Ventures
“We aren’t building another accelerator or passive investment firm,” said Katie Hotze, President of Crave Ventures. “By using advanced techniques, we’re expediting the growth of our portfolio brands and bridging the gap between advice and outcomes.”
Crave is built like an agency and backed like a VC, surrounding founders with a marketing and creative studio, retail placement experts, a PR team and strategic advisers. At Crave, there are no classes, cohorts or curriculums.
Crave Labs, Crave’s in-house agency, amplifies discovery, content and third-party endorsements while partner Alliance Sales & Marketing, the largest natural food brokerage in the U.S., opens doors to retail opportunities typically out of reach for early-stage brands.
“Crave is the continuum I wish had existed for so many breakout products that crossed my desk over the past 20 years at Alliance,” said Scott Anderson, founder and CEO of Alliance Sales and Marketing and lead adviser to Crave Ventures. “The CPG playbook has changed, and early-stage founders need an operator partner with skin in the game and a team that has built and led brands to exit.”
Crave offers the following program benefits to its portfolio founders:
Scaling from the inside out. Crave’s senior team plans, builds and runs brand, growth and retail programs alongside its portfolio founders.
Retail access that wins. With Alliance Sales & Marketing, Crave establishes trusted buyer relationships and velocity-minded retail activation.
AI-driven growth. Crave delivers access to industry-leading tools in retail discovery, reviews, creators, media and sampling.
Warm investor pathways. Crave accelerates capital readiness and facilitates introductions that convert traction into funding.
Storytelling that drives behavior change. Crave Labs delivers marketing, branding, creative, media and PR strategies that grow brand equity and market share.
Crave partners with pre-seed and seed-stage CPG brands and co-builds with founders through exit. Applicants are pre-screened for growth potential and vetted via a thorough interview and selection process. The firm accepts applications on a rolling basis.
About Crave Ventures Crave Ventures is a first-of-its-kind execution and growth partner for early-stage CPG founders. Through its continuum model, the firm invests services for equity in pre-seed and seed-stage brands, unlocking access to world-class marketing, PR, retail, technology and investor networks. Crave meets founders where they are and co-builds with them through exit. Crave is backed by Alliance Sales & Marketing and is advised by industry veteran Scott Anderson.
– Current CEO and Co-founder Nancy Briefs Transitions to Executive Chair of the Board –
– Financing and Leadership Transition Strengthen Momentum Toward First Clinical Trial of AJN 003 for Type 2 Diabetes –
LOWELL, Mass., Sept. 16, 2025 — AltrixBio, a biopharmaceutical company pioneering treatments for cardiometabolic diseases, announced the closing of an initial $5 million Series A financing. The funding will accelerate the clinical entry of AJN 003 (LuCI™ – Luminal Coating of the Intestine), a first-in-class oral therapy designed to transform the treatment of type 2 diabetes and metabolic diseases.
David Pass
In addition, the company has appointed David Pass, PharmD, as president andchief executive officer. Dr. Pass brings decades of leadership experience across the pharmaceutical, biotech and medical device sectors with a proven record of scaling programs from concept to more than $1 billion in sales. He succeeds AltrixBio Co-founder and CEO Nancy Briefs, who successfully guided the company from inception, and will now serve as executive chair of the board.
“It is an honor to join AltrixBio at such a pivotal moment,” said Dr. Pass. “I am inspired by the potential of AJN 003 both to change the way we think about the science of type 2 diabetes and metabolic disorders, and to bring the often life-changing benefits of bariatric surgery into a pill.”
New investment driven by AJN 003 transformational approach
AltrixBio is developing AJN 003 (LuCI™), a once-daily oral pill that temporarily coats the stomach, duodenum and jejunum to mimic the powerful metabolic effects of bariatric surgery without the associated risks. Bariatric surgery has demonstrated rapid improvements in glucose control with diabetes remission in most patients, along with significant weight loss. Preclinical studies of AJN 003 have shown similar gut hormone and metabolic responses, while avoiding systemic drug exposure and associated safety concerns.
The Series A financing will support AltrixBio in advancing AJN 003 into human clinical studies, aiming to provide an oral therapy for type 2 diabetes, obesity and other metabolic diseases. This novel treatment approach offers an enormous global commercial opportunity.
Leadership transition marks next phase
The appointment of Dr. Pass as CEO marks a new chapter for AltrixBio as the company prepares to bring its lead candidate, AJN 003, into the clinic. Dr. Pass joins AltrixBio after successfully building and leading the Diabetes Franchise with the alliances between Eli Lilly and Boehringer Ingelheim and, most recently, serving as president of Life Sciences at Glooko.
“I am confident that David will successfully lead the company into its next era of clinical and commercial activities,” said Briefs. “I am incredibly proud of what we have achieved together and am excited to continue supporting the company as executive chair of the board.”
“This transition reflects our ongoing commitment to leadership excellence and long-term value creation,” said Ali Tavakkoli, MD, co-founder and board member. “We are grateful to Nancy for her visionary leadership and are thrilled to welcome David as our new CEO. His expertise and passion for our mission will be instrumental as we continue to deliver on our vision of ‘Surgery in a Pill®'”.
About AJN003 (LuCI™)
AJN 003 (LuCI™ – Luminal Coating of the Intestine) is a once-daily oral therapy that forms a temporary barrier in the stomach, duodenum and jejunum to replicate the metabolic benefits of bariatric bypass surgery. Preclinical data show that AJN 003 alters nutrient sensing in this region of the gut, and triggers the same hormone and metabolic responses associated with bariatric surgery. AJN 003 is a small molecule with no systemic exposure, providing a novel and patent-protected approach to treating type 2 diabetes, obesity and other metabolic diseases.
About AltrixBio Founded in 2019, AltrixBio builds on research from Jeff Karp, PhD, and Ali Tavakkoli, MD, of Mass General Brigham and Harvard Medical School. Their work was inspired by the rapid resolution of type 2 diabetes often observed in patients following bariatric surgery. They hypothesized that sucralfate, an established therapy with over 40 years of clinical use, could be modified to replicate these metabolic benefits. This research led to the development of AJN 003 (LuCI™ – Luminal Coating of the Intestine), a proprietary, bio-engineered form of sucralfate developed as a once-daily oral therapy. The AltrixBio team comprises scientists, clinicians and industry business leaders with deep scientific, operational and commercial expertise.
Forward-Looking Statements
This press release contains forward-looking statements regarding the leadership transition and future plans of AltrixBio. Actual results may differ materially from those projected in these statements. For more information, please refer to the company’s filings with the relevant securities authorities.
For further updates and information, please visit AltrixBio.com
Breakthrough investment showcases momentum of virtual fencing technology, as Nofence advances scalable, tech-driven grazing solutions for livestock management
ST. PAUL, Minn., Sept. 16, 2025 — Nofence, the leading innovator in virtual fencing technology, announced today that it has raised over $35 million (€30 million) after the successful close of its Series B funding, which concluded in July. As Europe’s largest agtech funding round of 2025, this investment signals investor confidence in Nofence’s market traction, product innovation, and long-term potential to transform livestock management in the U.S. and worldwide.
The new capital is announced on the heels of the company’s recent hirings of Alex Bell as managing director in the U.S. and Eric Yates as national sales director. These investments were led by international firms with deep expertise in climate tech, agtech, and sustainable systems, including the lead investor European Circular Bioeconomy Fund, along with Capagro, Nysnø Climate Investments, Climate Innovation Capital, and Speedinvest – while existing investors Sandwater, Momentum, and Ferd are also continuing their commitment, reflecting strong support for Nofence’s role in providing more sustainable and efficient grazing solutions for cattle, sheep, and goat farmers alike.
As the pioneer of virtual fencing and the company with the longest experience in the field, the new funding will enable Nofence to accelerate its worldwide expansion in key North American and European markets. It underscores the company’s continued momentum in advancing its technology through further product development, strengthening service to its growing customer base, and reinforcing its position in core markets, including in the U.S. and E.U. Nofence recognizes the trust and support farmers and ranchers placed in its technology and is committed to using the new capital to further invest in enhancing its ability to serve them and deliver greater value. Nofence’s solar-powered, GPS-enabled collars managed via its easy-to-use mobile app are already helping thousands of farmers and ranchers improve land stewardship and reduce labor and production costs.
“Nofence’s virtual fencing is transforming the way livestock producers manage their herds by enabling rotational grazing – an effective climate measure in agriculture – while also offering more efficient solutions to better monitor and enhance the welfare of livestock, reduce costs, and provide peace of mind,” said Joachim Kähler, CEO of Nofence. “This Series B funding is more than a financial milestone; it further validates our vision and the real-world results we’ve delivered to farmers across the globe. This raise reflects the strength of our team, the loyalty of our customers, and the urgency of the challenges we’re helping to solve, positioning us to make virtual fencing the standard for livestock management globally.”
“Farmers and ranchers are looking for tools that give them greater flexibility and insight in how they manage their land and livestock, and Nofence’s virtual fencing technology is delivering for those needs,” said Alex Bell, U.S. Managing Director for Nofence.“With Nofence, our customers are able to work more efficiently and steward their land more sustainably. These investments mark a major step forward for Nofence in the U.S., expanding our reach and accelerating our ability to deliver even more value to our customers.”
“We are incredibly proud to announce our Series B funding round. This investment is a testament to the hard work of the entire Nofence team and the strength of our technology,” said Stefanie Witte, Chair of Nofence’s Board of Directors. “What’s particularly exciting for us is not just the capital, but the calibre and international breadth of our investors. They bring a range of expertise from across Europe and North America – perfectly aligned with Nofence’s own international expansion, and their experience will be an invaluable asset as Nofence continues to grow and innovate.”
“At ECBF, we back companies that scale commercially while driving sustainable, resource-efficient systems. Nofence is transforming livestock management with a solution that improves efficiency, lowers costs, while restoring soil and biodiversity,” highlighted Isabelle Laurencin, Partner at ECBF. “With strong traction in Europe and clear U.S. growth prospects, we are proud to back this ambitious team as they set a new standard for sustainable agriculture.”
“Nofence is addressing one of the most urgent needs in agriculture: making livestock management more efficient and climate-friendly. The company’s rapid adoption across multiple markets demonstrates both the strength of its technology and the depth of demand from farmers. Having backed Nofence since the Series A, Sandwater is proud to continue this partnership and build on the strong foundation already in place,” says Torkel Engeness, Partner at Sandwater.
“We have known Nofence for a long time and continue to be impressed by their execution across markets. With farm digitization still in its early stages, Nofence stands out as a key enabler, creating a strong platform for new products beyond virtual fencing,” emphasized Wissam Nasreddine, Principal at Speedinvest.
Since entering the U.S. market in 2025, Nofence has seen surging demand among American producers eager to improve grazing management without the constraints of physical fencing. As the world’s only provider of virtual fencing for both cattle and small ruminants, Nofence technology is helping American producers in 48 states manage their livestock more efficiently, all while saving time and money.
About Nofence and the technology Founded in Norway in 2011 by goat farmer Oscar Hovde at Batnfjordsøra, Nofence is the world’s pioneer commercial virtual fencing system for livestock, serving as a sustainable alternative to physical fencing. The animals’ grazing areas are managed using a GPS collar, which communicates with an app using a mobile network. When the animals cross the virtual boundary, an escalating acoustic warning is played. If they ignore the sound, they will get a mild but effective electrical pulse. The animals learn this quickly in their training period of up to a week, depending on variables like the breed and the age of the animal. The collars can be bought online at nofence.co/us.
The company’s virtual fences have increased in popularity since its pilot customers first began using it in Norway in 2016, with the company surpassing 150,000 collars sold – a strong testament to the success of the new technology. Nofence has 90 employees worldwide, distributed between Norway, the UK, Ireland, Spain, and the United States.
About the Investors Capagro is Europe’s first independent venture capital fund dedicated to AgTech and FoodTech innovation. With approximately €240 million under management and backing from leading agrobusinesses and institutional LPs, Capagro supports startups across the entire agri-food value chain, accelerating the adoption of impactful technologies, from smart agriculture to sustainable food solutions.
Climate Innovation Capital (CIC) is a growth equity fund investing in mid-stage climate technology companies that deliver measurable decarbonization and strong financial performance. With deep operational and investment expertise, CIC targets solutions across key sectors like energy, buildings, transportation, and food systems. Its portfolio companies are reshaping industries by turning climate innovations into scalable, cost-competitive businesses.
European Circular Bioeconomy Fund (ECBF) is the leading venture capital impact fund exclusively focused on the circular bioeconomy. With $350 million (€300 million) AUM, ECBF invests $2.3-11.6 million (€2–10 million) in high-potential growth-stage companies across sectors like agtech, food, industrial biotech, and biomaterials. The fund aims to help Europe transition to a climate-neutral, nature-aligned economy by 2050, in line with the European Environmental Goals.
Nysnø Climate Investments is a state-owned investment company that invests in companies and funds with technology for reducing greenhouse gas emissions. Nysnø has assets under management of NOK 5.4 billion and invests in renewable energy, digital technologies, resource efficiency, sustainable consumption, and the circular economy. The company is headquartered in Stavanger and is owned by the Ministry of Trade, Industry, and Fisheries.
Speedinvest is one of Europe’s most active early-stage venture capital firms, with over €1 billion in assets under management. Its sector-focused teams and in-house experts provide founders with hands-on support across growth, operations, and business development. Speedinvest backs bold entrepreneurs across deep tech, fintech, climate tech, SaaS, and more.
Sandwater is a Nordic venture capital firm investing in early-stage growth companies in resource efficiency, energy transition and productivity and resilience. Sandwater was established in 2021 by a team with extensive industry experience.
Momentum is a Norwegian venture fund aiming to accelerate sustainability, efficiency, and resilience across energy, food/agriculture, and industry. Momentum typically invests at the seed stage and actively supports its portfolio companies through their growth stages.
Ferd is a family-owned Norwegian investment company committed to value-creating ownership across both businesses and financial assets. Ferd is invested in Nofence through Ferd Impact Investing, which invests in early-stage climate tech companies and funds that have the potential to deliver both a positive climate and environment impact and a solid risk-adjusted return.
